PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma - Wikidata - wikimedia - TriplyDB

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

http://www.wikidata.org/entity/Q34667977

about

Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab Prospects of immune checkpoint modulators in the treatment of glioblastoma Phenylethanoid Glycosides from Cistanche tubulosa Inhibits the Growth of B16-F10 Cells both in Vitro and in Vivo by Induction of Apoptosis via Mitochondria-dependent Pathway Clinical and biological determinants of melanoma progression: Should all be considered for clinical management?The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1.CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials.MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer.Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response.Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma.Trial Watch: Immunotherapy plus radiation therapy for oncological indications.Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor The current management of brain metastasis in melanoma: a focus on riluzole.Nivolumab: A Review in Advanced Melanoma.Stimulating immune responses to fight cancer: Basic biology and mechanisms.Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.Mechanistic and pharmacologic insights on immune checkpoint inhibitors.Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings.Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.MALT1 promotes melanoma progression through JNK/c-Jun signaling Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways.Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.Improving anti-melanoma effect of curcumin by biodegradable nanoparticles.Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.[Autoimmune reactions to immune checkpoint inhibitors].Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.Immunotherapy in managing metastatic melanoma: which treatment when?Lymphocytic hypophysitis: modern day management with limited role for surgery.

P2860

Q26765060-5693AC84-A7BE-4775-8F2A-EF79D742E5DB Q26797478-075058D9-36EE-4617-B123-CA3D46A8B3D6 Q28073874-9ABC0223-335D-4397-9960-B2D8B53DC355 Q28081371-5BBCF542-87A5-4E95-A055-9B4D9CCE4118 Q28598311-A728D1E5-2D98-43AF-B862-C9E4FA4D1D82 Q30252150-66DD7270-8968-4A23-A18B-7CA6E9FDCDC4 Q33591618-464A6B8E-F14F-48D7-B3AF-592BE87326C8 Q36512076-8D62DE91-8578-45C4-94AB-6962C06B5039 Q36716229-A6EC4153-9855-4442-AB6C-EBE0A7A78D8A Q36782579-AC7CD265-0FB6-48EA-A162-78A424B1DC6C Q37222127-2A5A58E7-50E1-42D8-A673-9C941320BDCC Q37308192-92243653-23F9-4567-A92A-6A8F1E1BBBE3 Q37308207-C1AE7AFC-0A71-4E28-A2D3-FA2532CCE4E7 Q37536649-4A9D302E-6AEC-47F3-A41F-106315F494FA Q37565475-4406D6CF-8C29-417C-800A-923FD26C9EDA Q37662169-6C64E4FC-0482-463C-971F-50B38281C232 Q38532696-6481646B-3747-4119-B246-8866FE4FB549 Q38556639-03E4D4D3-0EE3-449A-BD8E-0D2C0A1D9B79 Q38578898-C4326694-DE83-4D81-96B4-9B285DE24469 Q38783026-5BD798DA-7760-4C3D-AF64-4F3E0440B874 Q38799409-22A89D0B-171B-4ACF-8128-3984224AFBD0 Q39039083-779A75ED-97DE-409C-91F9-2F04A72FBF5E Q39190066-59D106C1-6BFA-47D7-A0BF-A4576D1484A9 Q40076388-43DE25FB-E5E1-48FF-B287-A2438A753FB0 Q40535967-4E21A715-B819-46E3-8A87-095F3DFF3AF2 Q41228856-D208EEA1-C5F4-4BEF-867D-C22FCDF6121B Q41590737-619576F0-CCFC-443C-AEAF-3336B6E3844A Q42290800-E8C2D557-143B-4EE6-B075-201CDB6EAD9B Q43084076-0D4D0077-9232-49FB-B441-64C2268883A2 Q46721978-AAA39FCE-431A-4AF1-A475-3B7B6849B04B Q47101631-76A0F16E-5A14-4DB0-BEAD-2D3CD04ABC37 Q47102520-34AE46A2-CF84-4DBE-AF55-AD9A2CA77981 Q47104348-535103B0-0F28-4004-9BAA-94716C079688 Q47211602-47666304-835A-43DB-B911-9C10C4AF79BA Q48128794-9E4AF3F3-6C41-41F7-9211-2289B52D5D47 Q49188770-1219BE1C-62AD-4B83-B339-B65966F3AF89 Q50057565-748AAA7A-2FAE-45A2-B623-0AA63561B4C5 Q50143789-8A11B424-844A-4D59-A45D-B4E74C7851DF Q50166276-905E619F-3E77-4112-8488-3B22FF7D8099 Q51751740-E1B93CBB-12CA-4E71-8B4B-423CF25702EA

P2860

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

http://www.wikidata.org/entity/Q34667977

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

@ast

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

@en

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

@nl

type

label

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

@ast

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

@en

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

@nl

prefLabel

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

@ast

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

@en

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

@nl

P1433

Q34667977-1FA9EFC5-9F98-4C42-8AB9-48E3C5688805

P1476

Q34667977-E63C877A-D2C6-43F8-BDE0-6F31A639C4D2

P2093

Q34667977-AA05D0A3-0333-4534-99BF-8C815A377B02

Q34667977-C77C7F90-0A8D-442B-8DCA-6E1CC1218248

P275

Q34667977-00B7E4CA-CD61-4F44-AA1B-2E38C98D74E1

P2860

Q34667977-01E4A12B-D6F2-423D-AA8E-3F1E58A80118

Q34667977-07A639BD-D412-4531-8CAB-680265D83282

Q34667977-0996CF39-FCAA-4BD1-8DFC-7D7863483984

Q34667977-0E5104B3-D43A-4464-B07C-E02677822B66

Q34667977-0E6282E3-E6E4-4D81-B2C0-02DBDFD0E160

Q34667977-10D183D8-A712-4A59-834D-30E5981308FF

Q34667977-1314950B-4AA1-43B2-B2A7-145BF8F32E58

Q34667977-179A3940-2F33-4F43-BE3B-EB5083FADA86

Q34667977-1F2BC016-DFCC-433B-B05F-3A74CA253192

Q34667977-25E0CCEB-1063-46B6-9CF6-D2C5524C615B

P304

Q34667977-7AC1BF20-05D4-4490-BC9B-835C6251D768

P31

Q34667977-A33E0302-CABD-4885-AC56-449D5D86943F

Q34667977-DE83CFB3-3DFB-4A6A-AFBF-5CB9D04AAA10

P356

Q34667977-AE71FD1A-641B-422F-BF96-E9A7AD25EE2F

P407

Q34667977-E929ECD7-517F-48FB-9BDB-488C2AC61845

P433

Q34667977-BF95BC45-C33F-4480-9D90-A82D064D3478

P478

Q34667977-3D2D4021-E26A-418D-9045-5D8BFD415C61

P5008

Q34667977-999B90B8-B23E-4457-B154-4801055A8992

P577

Q34667977-130F5B7D-E436-4CEA-90A5-10419F566856

Q34667977-19CF40D6-50A0-46FD-99AB-42789E975C7B

P5875

Q34667977-E5C19AFE-E3E2-426D-A9F4-01189ED2E6CD

P698

Q34667977-81BCFC3F-55A7-4153-990A-7285CDCAFDF7

P921

Q34667977-012AB065-5A6B-462F-AB9C-89A307D58142

Q34667977-16B815BD-B9A4-41F4-BFC8-090F0791A3AB

Q34667977-6E6F6103-2096-4CBC-8DC9-E3AB30081488

Q34667977-E07B38F4-227E-4619-8691-74CF402B7630

P932

Q34667977-74C3A7A0-517A-4E91-9EAF-5CDDFA57E28A

P356

ONCOTARGET.2980

P1433

P1476

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

@en

P2093

Jason J Luke

http://www.w3.org/2001/XMLSchema#string

Patrick A Ott

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

The blockade of immune checkpoints in cancer immunotherapy

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

P304

3479-3492

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2980

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2015-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272355188

http://www.w3.org/2001/XMLSchema#string

P698

25682878

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

membrane proteins

P932

4414130

http://www.w3.org/2001/XMLSchema#string